000150248 001__ 150248
000150248 005__ 20250131203739.0
000150248 0247_ $$2doi$$a10.1016/j.ijpharm.2021.121014
000150248 0248_ $$2sideral$$a126066
000150248 037__ $$aART-2021-126066
000150248 041__ $$aeng
000150248 100__ $$0(orcid)0000-0001-6139-5905$$aPaz-Artigas, L$$uUniversidad de Zaragoza
000150248 245__ $$aBenefits of cryopreservation as long-term storage method of encapsulated cardiosphere-derived cells for cardiac therapy: A biomechanical analysis
000150248 260__ $$c2021
000150248 5203_ $$aCardiosphere-derived cells (CDCs) encapsulated within alginate-poly-L-lysine-alginate (APA) microcapsules present a promising treatment alternative for myocardial infarction. However, clinical translatability of encapsulated CDCs requires robust long-term preservation of microcapsule and cell stability, since cell culture at 37 degrees C for long periods prior to patient implantation involve high resource, space and manpower costs, sometimes unaffordable for clinical facilities. Cryopreservation in liquid nitrogen is a well-established procedure to easily store cells with good recovery rate, but its effects on encapsulated cells are understudied. In this work, we assess both the biological response of CDCs and the mechanical stability of microcapsules after long-term (i.e., 60 days) cryopreservation and compare them to encapsulated CDCs cultured at 37 degrees C. We investigate for the first time the effects of cryopreservation on stiffness and topographical features of microcapsules for cell therapy. Our results show that functionality of encapsulated CDCs is optimum during 7 days at 37 degrees C, while cryopreservation seems to better guarantee the stability of both CDCs and APA microcapsules properties during longer storage than 15 days. These results point out cryopreservation as a suitable technique for long-term storage of encapsulated cells to be translated from the bench to the clinic.
000150248 536__ $$9info:eu-repo/grantAgreement/EC/H2020/78132/EU/Electronic Components and Systems for European Leadership Joint Undertaking/ECSEL JU-78132-Position-II-2017-IA$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 78132-ECSEL JU-78132-Position-II-2017-IA
000150248 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000150248 590__ $$a6.51$$b2021
000150248 591__ $$aPHARMACOLOGY & PHARMACY$$b40 / 279 = 0.143$$c2021$$dQ1$$eT1
000150248 592__ $$a1.0$$b2021
000150248 593__ $$aPharmaceutical Science$$c2021$$dQ1
000150248 594__ $$a9.6$$b2021
000150248 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000150248 700__ $$aZiani, K
000150248 700__ $$0(orcid)0000-0002-7854-8856$$aAlcaine, C$$uUniversidad de Zaragoza
000150248 700__ $$aBaez-Diaz, C
000150248 700__ $$aBlanco-Blazquez, V
000150248 700__ $$aPedraz, JL
000150248 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, I$$uUniversidad de Zaragoza
000150248 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza, J$$uUniversidad de Zaragoza
000150248 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000150248 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000150248 773__ $$g607 (2021), 121014 [10 pp]$$pInt. j. pharm.$$tInternational Journal of Pharmaceutics$$x0378-5173
000150248 8564_ $$s5604064$$uhttps://zaguan.unizar.es/record/150248/files/texto_completo.pdf$$yVersión publicada
000150248 8564_ $$s2454259$$uhttps://zaguan.unizar.es/record/150248/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000150248 909CO $$ooai:zaguan.unizar.es:150248$$particulos$$pdriver
000150248 951__ $$a2025-01-31-20:05:35
000150248 980__ $$aARTICLE